| Project/Area Number |
20K20237
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 90130:Medical systems-related
|
|---|
| Research Institution | Okinawa Institute of Science and Technology Graduate University |
|---|
Principal Investigator |
Funari Riccardo 沖縄科学技術大学院大学, マイクロ・バイオ・ナノ流体ユニット, 研究員 (20866058)
|
|---|
| Project Period (FY) |
2020-04-01 – 2021-03-31
|
| Project Status |
Completed (Fiscal Year 2020)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2021: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2020: ¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
|
|---|
| Keywords | Biosensor / Prostate cancer / SARS-CoV-2 / Cancer biomarkers / dual-mode sensing / Antibody |
|---|
| Outline of Research at the Start |
The outline of the research consists of three key points:
1) Optimization of the gold nanostructures on the QCM sensor surface to perform both optical and microgravimetric sensing.
2) Quantification of prostate cancer biomarkers by antibody-based biosensors.
3) Capturing the presence of the target molecules in real biological samples.
|
| Outline of Annual Research Achievements |
I was able to develop an opto-microfluidic sensing platform to detect specific biomarkers in human plasma. The ongoing global pandemic of SARS-CoV-2 motivated us to use this device to detect first COVID-19 related proteins such as anti-SARS-CoV-2 S antibodies (DOI: 10.1016/j.bios.2020.112578).
This device has been further developed to achieve the detection of multiple biomarkers in the same sample using a single integrated device, and is the subject of a recently submitted pubblication about COVID-19 reasarch and of a next paper on prostate cancer biomarkers detection in human plasma. Specifically, this biosensor allows to detect prostate specific antigen, matrix metalloproteinase-2 and anti-alpha-methylacyl-CoA in real sample with high sensitivity (LOD < 0.5 ng/mL) in less than 30 min.
|
